UK-based specialty pharma group Essential Pharma has bought the Reminyl (galantamine hydrobromide) product line from Johnson & Johnson (NYSE: JNJ).
An oral cholinesterase inhibitor, Reminyl is an established central nervous system (CNS) drug indicated for the treatment of mild to moderately severe dementia of the Alzheimer type.
The acquisition further expands Essential’s presence globally, particularly in the Asia-Pacific region.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze